Cormorant Asset Management, LP Altimmune, Inc. Transaction History

Cormorant Asset Management, LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$8.74 - $16.45 $7.37 Million - $13.9 Million	-842,863 Reduced 24.48%	2,600,000 $42.8 Million
Q3 2022 Nov 14, 2022	BUY	$10.67 - $22.41 $4.73 Million - $9.92 Million	442,863 Added 14.76%	3,442,863 $44 Million
Q2 2022 Aug 15, 2022	BUY	$3.94 - $11.77 $11.8 Million - $35.3 Million	3,000,000 New	3,000,000 $35.1 Million

208

39.5M

1.94M

1.38M

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $315M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.